Please assess the completion status of the following clinical trial:

Trial Title: A Study of Momelotinib Versus Danazol in Symptomatic and Anemic Myelofibrosis Participants (MOMENTUM)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age \>= 18 years.~* Confirmed diagnosis of PMF in accordance with the World Health Organization (WHO) 2016 criteria, or Post- polycythemia vera/essential thrombocythemia (PV/ET) MF in accordance with the International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT criteria).~* Symptomatic, defined as a TSS of \>= 10 units assessed by a single MFSAF v4.0 assessment during Screening prior to Baseline period (Day BL1).~* Anemic, defined as a Hgb \< 10 g/dL in Screening/Baseline period.~* Previously treated with an approved JAK inhibitor for PMF or Post-PV/ET MF for \>= 90 days, or \>= 28 days if JAK inhibitor therapy is complicated by RBC transfusion requirement of \>= 4 units in 8 weeks, or Grade 3/4 AEs of thrombocytopenia, anemia, or hematoma.~* Baseline splenomegaly, defined as having a palpable spleen at \>= 5 centimeter (cm), below the left costal margin, or with volume \>= 450 cubic centimeter (cm\^3) on imaging (ultrasound, magnetic resonance imaging \[MRI\] or computed tomography \[CT\] are acceptable), assessed during Screening at any point prior to Randomization.~* High risk, intermediate-2, or intermediate-1 risk MF as defined by Dynamic International Prognostic Scoring System (DIPSS), or DIPSS-plus.~* No allogeneic stem cell transplant planned.~* Acceptable laboratory assessments:~  1. Absolute neutrophil count (ANC) \>= 0.75 × 10\^9/Liter (L).~ 2. Platelet count (PLT) \>= 25 × 10\^9/L (without requirement for platelet transfusion).~ 3. Peripheral blast count \< 10%.~ 4. Alanine aminotransferase/ glutamic-oxaloacetic transaminase (AST/SGOT) and alanine aminotransferase/ serum glutamic-pyruvic transaminase (ALT/SGPT) \<= 3 × Upper Limit Normal (ULN) (\<= 5 × ULN if liver is involved by extramedullary hematopoiesis as judged by the investigator or if related to iron chelator therapy that was started within the prior 60 days).~ 5. Calculated creatinine clearance (CCr) \>= 30 milliliter per minute (mL/min) according to Cockcroft-Gault.~ 6. Direct bilirubin \<= 2.0 × ULN.~Exclusion Criteria:~* Use of the following treatments within the time periods noted:~  1. Prior momelotinib treatment at any time.~ 2. Approved JAK inhibitor therapy (eg, fedratinib or ruxolitinib) within 1 week prior to the first day of Baseline.~ 3. Active anti-MF therapy within 1 week prior to the first day of Baseline.~ 4. Potent Cytochrome P450 3A4 (CYP3A4) inducers within 1 week prior to Randomization.~ 5. Investigational agent (including investigational JAK inhibitors) within 4 weeks prior to Randomization.~ 6. Erythropoiesis stimulating agent (ESA) within 4 weeks prior to Randomization.~ 7. Danazol within 3 months prior to Randomization.~ 8. Splenic irradiation within 3 months prior to Randomization.~ 9. Current treatment with simvastatin, atorvastatin, lovastatin or rosuvastatin.~* History of prostate cancer, with the exception of localized prostate cancer that has been treated surgically or by radiotherapy with curative intent and presumed cured.~* Prostate specific antigen (PSA) \> 4 nanograms per milliliter (ng/mL).~* Unsuitable for spleen volume measurements due to prior splenectomy or unwilling or unable to undergo an MRI scan or CT scan for spleen volume measurement per protocol requirements.~* Any of the following (criteria a - k):~  1. Uncontrolled intercurrent illness including, but not limited to: active uncontrolled infection (participants receiving outpatient antibacterial and/or antiviral treatments for infection that is under control or as infection prophylaxis may be included in the trial).~ 2. Significant active or chronic bleeding event \>= Grade 2 per Common Terminology Criteria for Adverse Events (CTCAE) v5.0, within 4 weeks prior to Randomization.~ 3. Unstable angina pectoris within 6 months prior to Randomization.~ 4. Symptomatic congestive heart failure within 6 months prior to Randomization.~ 5. Uncontrolled cardiac arrhythmia within 6 months prior to Randomization.~ 6. QT Interval Corrected Using Fridericia's Formula (QTcF) interval \> 500 millisecond (msec), unless attributed to bundle branch block.~ 7. Current progressive thrombosis despite treatment.~ 8. History of porphyria.~ 9. Child-Pugh score \>= 10.~ 10. Psychiatric illness, social situation, or any other condition that would limit compliance with trial requirements or may interfere with the interpretation of study results, as judged by investigator or sponsor.~ 11. Inability or unwillingness to comply with the protocol restrictions on MF therapy and other medications prior to and during study treatment.~* Participants with a prior or concurrent malignancy, whose natural history or treatment has a significant potential to interfere with the safety or efficacy assessment of the investigational regimen.~* Known clinically significant anemia due to iron, vitamin B12, or folate deficiencies, or autoimmune or hereditary hemolytic anemia, or gastrointestinal bleeding or thalassemia.~* Known positive status for human immunodeficiency viruses (HIV).~* Chronic active or acute viral hepatitis A, B, or C infection, or hepatitis B or C carrier (testing required for hepatitis B and C).~* Unresolved non-hematologic toxicities from prior therapies that are \> Grade 1 per CTCAE v5.0.~* Presence of peripheral neuropathy \>= Grade 2 per CTCAE v5.0.~* Women who are already pregnant or lactating. Additional inclusion/exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Momelotinib (Type: EXPERIMENTAL): Participants will receive momelotinib plus placebo to match danazol
- Danazol (Type: ACTIVE_COMPARATOR): Participants will receive danazol plus placebo to match momelotinib

Based on this trial design, predict the completion outcome and termination type (if applicable).